Yuhan Clinical Trials

Clinical trials sponsored by Yuhan — phases, conditions and reported results. Data from ClinicalTrials.gov.

• Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Loca
  Phase 3 · Non-Small Cell Lung Cancer · Completed · Mar 22, 2024
• A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced
  Phase 1/2 · Carcinoma, Non-Small-Cell Lung · Completed · Feb 28, 2024
• Bioequivalence Study of Letrozole 2.5 mg Tablets
  N/A · Healthy · Completed · Mar 29, 2019

Trials by company

PfizerMerck (MSD)RocheNovartisAstraZenecaJohnson & Johnson (Janssen)Bristol Myers SquibbSanofiGSKEli LillyAbbVieAmgenBayerBoehringer IngelheimNovo NordiskTakedaGilead SciencesModernaBioNTechRegeneronVertexBiogenDaiichi SankyoAstellas PharmaEisaiOtsukaServierIncyteCelltrionSamsung BioepisHanmi PharmaceuticalYuhan

All trials